BRAF and Miyoshi myopathy: However, in contrast to such dramatic progress, currently available therapies do not always result in patients with metastatic MM being cured, particularly in patients with tumors that lack a BRAF mutation as well as in patients with rare MM subtypes, such as uveal, acral, and mucosal MM due to either primary or acquired resistance following an initial response toward these targeted and non-targeted immune-based strategies [10].